Berlim 25/20 association(Berlim 25/20 association) - 在研适应症：2型糖尿病，血脂障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Berlim 25/20 association coated tablet

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病血脂障碍

非在研适应症-

原研机构

EMS SA (Brazil)

在研机构

EMS SA (Brazil)

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Berlim 25/20 association 相关的临床试验

NCT04602754 / Recruiting临床3期

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.

开始日期2023-12-01

申办/合作机构

EMS SA (Brazil)

NCT04603508 / Not yet recruiting临床3期

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.

开始日期2023-03-01

申办/合作机构

EMS SA (Brazil)

100 项与 Berlim 25/20 association 相关的临床结果

登录后查看更多信息

100 项与 Berlim 25/20 association 相关的转化医学

登录后查看更多信息

100 项与 Berlim 25/20 association 相关的专利（医药）

登录后查看更多信息

100 项与 Berlim 25/20 association 相关的药物交易

登录后查看更多信息